Lacosamide Tablet, Film Coated
Product Images NDC 46708-171

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Lacosamide (NDC 46708-171). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

30 Tablets (Lacosamide 100 mg)

Lacosamide Tablets, USP 100 mg film-coated tablets from Alembic Pharmaceuticals Limited. The label states each tablet contains 100 mg lacosamide and provides storage instructions and usual dosage note. The package contains 30 oral tablets, with barcode, lot, and expiration date fields visible.*

FDA Label Image

30 Tablets (Lacosamide 150 mg)

Label for Lacosamide Tablets, USP 150 mg, film-coated oral tablets in a package of 30 tablets. The label includes the NDC number 46708-173-30, manufacturer Alembic Pharmaceuticals Limited, storage instructions, and a barcode. It features dosage strength prominently in an orange box and indicates prescription use only.*

FDA Label Image

30 Tablets (Lacosamide 200 mg)

Label for Lacosamide Tablets, USP 200 mg film-coated tablets by Alembic Pharmaceuticals Limited. The label states prescription use only, package quantity of 30 tablets, and includes storage instructions. The NDC number 46708-174-30 and barcodes are also visible.*

FDA Label Image

30 Tablets (Lacosamide 50 mg)

Lacosamide Tablets, USP 50 mg film-coated oral tablets packaging label from Alembic Pharmaceuticals Limited. The label displays dosage strength (50 mg), tablet count (30 tablets), NDC 46708-171-30, storage instructions (20° to 25°C with permitted excursions), and a pharmacist warning about providing the patient guide.*

FDA Label Image

Figure1 (Lacosamide Figure 1)

A bar graph illustrating median percent reduction in seizure frequency over 28 days from baseline to maintenance phase by dose. It compares placebo and various lacosamide doses across three studies, showing seizure reduction percentages on the vertical axis and dose groups on the horizontal axis.*

FDA Label Image

Figure2 (Lacosamide Figure 2)

A line graph showing the proportion of patients by responder rate comparing lacosamide at 200 mg/day, 400 mg/day, 600 mg/day, and a placebo group across studies 2, 3, and 4. The vertical axis represents responder rate from -100% (worsening) to 100% (improvement), and the horizontal axis shows the percent of patients from 0 to 100%. Four lines illustrate the response rates for placebo and different lacosamide doses.*

FDA Label Image

Structure (Lacosamide Str)

Chemical structure of lacosamide, showing its molecular arrangement including an acetyl group, amide linkage, methoxy ester, and a phenyl ring connected to an aminoethyl side chain.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.